SCHEMBL3394416

SCHEMBL3394416

CCOC(=O)Cc1c(C)[nH]c2cc(F)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.44
PTGS2 P35354 3/20 0.44
KDM4E B2RXH2 4/20 0.44
LMNA P02545 2/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 3/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
KLK6 Q92876 1/20 0.42
ALOX15 P16050 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
AKR1C2 P52895 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
GLA P06280 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 1/20 0.40
ATM Q13315 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1191675 0.89 KDM4E (0.51) PTGS1PTGS2KDM4ELMNAALDH1A1
SCHEMBL8291790 0.84 JAK2 (0.47) KDM4ELMNAALDH1A1MAPTGAA
SCHEMBL31381374 0.83 KDM4E (0.63) PTGS1PTGS2KDM4EALDH1A1MAPT
SCHEMBL20048439 0.82 KDM4E (0.43) KDM4ELMNAALDH1A1MAPTGAA
SCHEMBL1165573 0.80 KDM4E (0.68) KDM4ELMNAALDH1A1MAPTGAA
SCHEMBL31487317 0.80 KDM4E (0.68) KDM4ELMNAALDH1A1MAPTGAA
SCHEMBL13229806 0.78 LMNA (0.47) KDM4ELMNAALDH1A1MAPTGAA
SCHEMBL11331437 0.78 KDM4E (0.49) KDM4ELMNAALDH1A1MAPTGAA
SCHEMBL9938004 0.78 GAA (0.60) PTGS1PTGS2LMNAALDH1A1MAPT
SCHEMBL8291738 0.78 KDM4E (0.69) KDM4ELMNAALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2024-12-12 US disclosed
US-20110060026-A1 Indoles Active on CRTH2 Receptor PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2011-03-10 US disclosed
EP-2245010-A1 INDOLES ACTIVE ON CRTH2 RECEPTOR Pulmagen Therapeutics (Asthma) Limited (GB) 2010-11-03 EP disclosed
WO-2009090399-A1 INDOLES ACTIVE ON CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060026-A1 Indoles Active on CRTH2 Receptor ARRB1, GPR3, HRH3 PTGS1 1454/4885PTGS2 1372/4885KDM4E 4402/4885
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS PTGS1 2106/4885PTGS2 2960/4885KDM4E 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.